Prism Pharma Co., Ltd.

Prism Biolab Co., Ltd.

Prism Biolab Corporation

Eisai R&d Management Co., Ltd.

Takenao Odagami

Hiroyuki Kouji

Yuji Kogami

Michinori Kohara

Yoichi Ozawa

Yusaku Hori

The present invention aims to provide a therapeutic drug for cancer having a superior treatment effect. A cancer treatment using a CBP/catenin inhibitor and an immune checkpoint inhibitor in combination not only increases a treatment effect on cancer, but also enables an effective treatment of cancer patients showing low sensitivity when an immune checkpoint inhibitor is used alone.

Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor

CBP/&#x3b2;-catenin inhibitor shows a superior defibrosing effect for Cre/loxP/HCV-MxCre transgenic mouse which is an animal experiment model of hepatic fibrosis, and useful as a prophylactic or therapeutic drug for hepatic fibrosis.

Prevention or treatment agent for hepatic fibrosis

Alpha-helix mimetic structures and compounds represented by the formula (I) wherein the general formula and the definition of each symbol are as defined in the specification, a chemical library relating thereto, and methods relating thereto, are disclosed. Applications of these compounds in the treatment of medical conditions, e.g., cancer diseases, fibrotic diseases, and pharmaceutical compositions comprising the mimetics are further disclosed.

Alpha helix mimetics and methods relating thereto

Alpha-helix mimetic structures and compounds represented by the formula (I) wherein the general formula and the definition of each symbol are as defined in the specification, a compound relating thereto, and methods relating thereto, are disclosed. Applications of these compounds in the treatment of medical conditions, e.g., cancer diseases, fibrotic diseases, and pharmaceutical compositions comprising the mimetics are further disclosed.

Alpha helix mimetic compositions for treating cancer and other CBP/catenin-mediated diseases and conditions

Alpha-helix mimetic structures and compounds represented by the formula (I) wherein the general formula and the definition of each symbol are as defined in the specification, a compound relating thereto, and methods relating thereto, are disclosed. Applications of these compounds in the treatment of medical conditions, e.g., cancer diseases, fibrotic diseases, and pharmaceutical compositions comprising the mimetics are further disclosed. 

Growing community of inventors

Yokohama, Japan

Takenao Odagami